Search

Your search keyword '"Buti, Maria"' showing total 1,749 results

Search Constraints

Start Over You searched for: Author "Buti, Maria" Remove constraint Author: "Buti, Maria"
1,749 results on '"Buti, Maria"'

Search Results

1. A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death

2. Emergency department contribution to HCV elimination in the Iberian Peninsula

5. Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study

7. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world

8. Stratified analyses refine association between TLR7 rare variants and severe COVID-19

9. Implementing a new HCV model of care for people who use drugs

10. Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation

16. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

17. Sequential PegIFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B

20. Characterizing Hepatitis Delta in Spain and the gaps in its management

21. Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination

22. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B

23. HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy

24. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

26. mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)

28. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

30. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

31. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

32. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

33. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

35. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study

37. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

39. Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort

40. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells

42. Recomendaciones para el diagnóstico integral de las hepatitis virales crónicas en una única extracción analítica

44. FRI-215-YI MASL-B registry: results from a european cohort of patients with chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease

45. TOP-400 Impact of bulevirtide given with or without nucleos (t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection

46. FRI-171 Paediatric solid organ transplant recipients (SOTR) demonstrate greater serological response to initial SARS-CoV-2 vaccination than adult SOTR, and comparable rates of antibody degradation

47. FRI-390 Off-treatment outcomes after discontinuing tenofovir-based treatment in hepatitis B e antigen-positive and hepatitis B e antigen-negative patients with chronic hepatitis B virus

48. LBP-044 Robust reduction of HBsAg and HDV RNA levels with low risk for ALT elevations in JNJ-73763989 treated patients with chronic hepatitis D (CHD) and baseline HBsAg levels below 10, 000 IU/ml: part 2 of the REEF-D study

49. OS-033 A phase 2 open-label study to evaluate safety, tolerability, efficacy, and pharmacodynamics of JNJ-73763989, nucleos (t)ide analogs, and a low-dose PD-1 inhibitor in patients with chronic hepatitis B-Interim results of the OCTOPUS-1 study

50. WED-411 The large (LHBs) and middle (MHBs) hepatitis B surface antigen are associated with response to bulevirtide or PEG-IFNa treatment in patients with chronic hepatitis Delta (CHD)

Catalog

Books, media, physical & digital resources